Evidence map›Paper›PMID 34376131›Full record

ArticleCurrent pharmaceutical biotechnology2022

Shibin Chen, Qiujie Xie, Ming Yang, Yajun Shi, Junhui Shi, Xiaobin Zeng

Open access · hybridAbstract read
In one paragraph

Article in Current pharmaceutical biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Research progress in brain-targeted nasal drug delivery.Frontiers in aging neuroscience · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Shibin ChenResearch Center, China Resources Sanjiu Medical & Pharmaceutical Co. Ltd., Shenzhen, 518110, China.
Qiujie XieCenter Lab of Longhua Branch and Department of Infectious Disease, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University), The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, 518020, PR China.
Ming YangCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.
Yajun ShiCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137,China.
Junhui ShiCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137,China.
Xiaobin ZengCenter Lab of Longhua Branch and Department of Infectious Disease, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University), The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, 518020, PR China.
Chengdu University of Traditional Chinese Medicine · CNJinan University · CNChina Resources (China) · CN

Funding

National Major New Drug Development Project 2009ZX09103-353
6 · The paper itself

Abstract

backgroundBaicalin, a flavonoid glycoside compound present in Scutellaria baicalensis, has shown a wide spectrum of biological activities, but its liposolubility, water-solubility and mucosal permeability are all very poor, which leads to the low concentration in brain and poor bioavailability by oral or intravenous injective administration.

objectiveThe primary objective of this study was to formulate the Scutellaria baicalensis extract (SBE) with phospholipid to yield Scutellaria baicalensis extract-phospholipid complex (SBEPC) , and to evaluate its pharmacodynamics in the middle cerebral artery occlusion (MCAO).

methodsThe optimal preparation technology of SBEPC was obtained through single-factor test and central composite design-response surface methodology (CCD-RSM), and was characterized with various analytical techniques including SEM, FT-IR and NMR. The storage conditions of SBEPC were established through stability study and the MCAO rat model was investigated through conducting pharmacodynamic studies to screen the appropriate administration and dose of SBEPC as well as to verify the neuroprotective effect of SBEPC on cerebral ischemia-reperfusion injury.

resultsThe optimized preparation conditions of SBEPC were summarized as follows: the ratio of phospholipids to drug was 2:1, the drug concentration was 3.5 mg/ml, the reaction temperature was 50 °C, and the entrapment efficiency was over 93.00%. Stability studies have demonstrated that SBEPC should be stored under 40 °C in a dry and ventilated place away from light and below 37% humidity. Furthermore, pharmacodynamic studies have found that, compared with SBE, SBEPC could introduce drugs into the brain and better exert the neuroprotective effect on MCAO rats, and the optimal administration and dose concentration of SBEPC were nasal administration and 40 mg/ml, respectively.

conclusionThese findings demonstrate that SBEPC is successfully prepared by CCD-RSM. SBEPC can enhance drugs' ability to enter the brain and improve the bioavailability of drugs in brain, and can effectively exert the neuroprotective effect on cerebral ischemia-reperfusion injury as compared with SBE.

Indexed as

FlavonoidsScutellaria baicalensisAnimalsPhospholipidsPlant ExtractsRatsSpectroscopy, Fourier Transform InfraredFlavonoidsPhospholipidsPlant ExtractsScutellaria baicalensis extractcentral composite design-response surface methodologycerebral ischemiapharmacodynamicsScutellaria baicalensis extract-phospholipid complexstability study

Identifiers

PMID34376131
PMCPMC9189737
OpenAlexW3190108997

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.